Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Total Current Liabilities (2016 - 2025)

Alterity Therapeutics has reported Total Current Liabilities over the past 5 years, most recently at $2.3 million for Q2 2019.

  • For Q2 2019, Total Current Liabilities rose 16.19% year-over-year to $2.3 million; the TTM value through Jun 2019 reached $2.3 million, up 16.19%, while the annual FY2019 figure was $2.3 million, 16.19% up from the prior year.
  • Total Current Liabilities for Q2 2019 was $2.3 million at Alterity Therapeutics, up from $2310.9 in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $2.3 million in Q2 2019 and troughed at $1194.8 in Q2 2017.
  • A 5-year average of $1.1 million and a median of $1.4 million in 2017 define the central range for Total Current Liabilities.
  • On a YoY basis, Total Current Liabilities climbed as much as 167422.61% in 2018 and fell as far as 99.83% in 2018.
  • Year by year, Total Current Liabilities stood at $1.7 million in 2015, then increased by 26.37% to $2.1 million in 2016, then plummeted by 34.7% to $1.4 million in 2017, then plummeted by 99.83% to $2310.9 in 2018, then skyrocketed by 100540.82% to $2.3 million in 2019.
  • Business Quant data shows Total Current Liabilities for ATHE at $2.3 million in Q2 2019, $2310.9 in Q4 2018, and $2.0 million in Q2 2018.